Today: 30 April 2026
Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts
30 December 2025
1 min read

Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

NEW YORK, December 30, 2025, 13:43 ET — Regular session

Shares of Energy Fuels Inc fell 3.5% to $14.55 in afternoon trading on Tuesday. The uranium miner lagged peers, with Uranium Energy down about 1.9% while Cameco was little changed and MP Materials slipped about 1.3%. Energy Fuels traded about 5.9 million shares and ranged between $14.30 and $15.28.

The pullback matters because uranium stocks have been swinging on fresh evidence of supply discipline, contract signings and realized pricing. Investors want proof that producers can turn high commodity prices into durable cash flow, not just headlines.

Energy Fuels is a live case study. It sells into both near-term spot markets and longer-dated contracts, a mix that can smooth revenue but also caps some upside.

In a company update on Monday, Energy Fuels said it exceeded its 2025 guidance for finished uranium production, mined ore and uranium concentrate sales. It expects to sell 360,000 pounds of U3O8 — uranium oxide concentrate, often called “yellowcake” — in the fourth quarter for about $27 million of gross uranium sales at a weighted average price of $74.93 per pound. “Strong uranium production is critical to America’s economic and national security,” CEO Mark S. Chalmers said. Energy Fuels

The company also said it completed two new long-term uranium sales contracts with U.S. nuclear power generators for deliveries from 2027 to 2032, using a hybrid pricing structure that blends an escalated base price with spot-price exposure within floor-and-ceiling bands. Energy Fuels forecast about 780,000 to 880,000 pounds of U3O8 sales into its long-term contract portfolio in 2026 and said its six long-term contracts total 2.41 million to 4.41 million pounds for 2027–2032; it also expects cost of goods sold to start dropping in the first quarter of 2026 as lower-cost uranium is sold. It said the White Mesa Mill produced more than one million pounds of finished U3O8 in 2025 and plans to mill roughly 250,000 pounds a month through the first half of 2026 before shifting to commercial-scale production of the heavy rare earths dysprosium and terbium.

Energy Fuels rose 2.94% on Monday to close at $15.07 after touching $16.00, then gave back ground in Tuesday’s session. The stock opened at $15.15 on Tuesday and was last trading below that level.

For investors, the contract mechanics are the key nuance. Hybrid pricing can support cash flow with a base component while still leaving some upside if uranium prices rise into delivery, but floors and ceilings limit the extremes.

Cost is the other swing factor. A drop in cost of goods sold — the direct costs tied to producing and processing uranium — would widen margins if realized prices hold, and it puts extra weight on how quickly lower-cost feed reaches sales.

The rare-earth angle adds optionality and complexity. Investors will be watching whether the company can execute on two commodity cycles at once, and how capital and operating priorities shift if one market tightens while the other cools.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout
Previous Story

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook
Next Story

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Go toTop